STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-04-19
Here’s whether Moderna, Inc. Common Stock (MRNA) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.51% over 10 days); RSI 63 — healthy momentum range; strong 1-year return of +113.3%; 3-month momentum positive (+28.4%). Currently 9.8% off its 52-week high. Score: +7/7.
MRNA is in a confirmed uptrend, trading above both its 50-day ($50.32) and 200-day ($34.80) moving averages. An RSI of 63.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +113.3% compares to +35.1% for SPY (beat the market by 78.2%).
$10,000 invested 1 year ago→ $21,326 today
vs. S&P 500 (SPY) — same period beat market by 78.2%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($34.80)
✓Above 50-day MA ($50.32)
✓RSI(14) neutral zone (30–70) — currently 63.3
✓Positive return (+113.3%)
✓Within 10% of period high (−9.8%)
Period Range $53.72
$22.28$59.55
RSI (14) 63.3
0 · OversoldOverbought · 100
Key Metrics
Price$53.72
Period Return+113.3%
Period High$59.55
Period Low$22.28
Drawdown−9.8%
MA-50$50.32
MA-200$34.80
RSI (14)63.3
Avg Volume (30d)6.9M
vs. SPYbeat by 78.2%
Return Rank#190 of 996
Trend Signals
Price is above the 200-day moving average ($34.80)